Femasys (NASDAQ:FEMY) Given “Buy” Rating at HC Wainwright

Femasys (NASDAQ:FEMY)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $12.00 price target on the stock.

Separately, Chardan Capital lowered their price target on shares of Femasys from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th.

Femasys Stock Up 7.8 %

Shares of NASDAQ:FEMY traded up $0.09 during trading on Tuesday, reaching $1.25. The stock had a trading volume of 527,125 shares, compared to its average volume of 196,673. Femasys has a one year low of $0.86 and a one year high of $2.40. The company has a market capitalization of $28.63 million, a P/E ratio of -1.54 and a beta of -2.81. The company has a current ratio of 3.94, a quick ratio of 3.26 and a debt-to-equity ratio of 0.86. The firm’s 50-day simple moving average is $1.13 and its 200 day simple moving average is $1.12.

Femasys (NASDAQ:FEMY) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. The firm had revenue of $0.55 million during the quarter, compared to the consensus estimate of $0.40 million. As a group, research analysts expect that Femasys will post -0.84 EPS for the current fiscal year.

Hedge Funds Weigh In On Femasys

Hedge funds and other institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC raised its position in Femasys by 9.2% during the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock worth $229,000 after buying an additional 17,473 shares during the last quarter. XTX Topco Ltd raised its position in Femasys by 123.9% during the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after buying an additional 18,004 shares during the last quarter. Virtu Financial LLC purchased a new position in Femasys during the 4th quarter worth approximately $25,000. Finally, Aljian Capital Management LLC purchased a new position in Femasys during the 3rd quarter worth approximately $27,000. 65.27% of the stock is owned by hedge funds and other institutional investors.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.